Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

<p>Supplementary Video 1</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Debarati Mukherjee (15134436) (author)
Diğer Yazarlar:	Rebecca A. Previs (16918344) (author), Corinne Haines (16918347) (author), Muthana Al Abo (16918350) (author), Patrick K. Juras (15134430) (author), Kyle C. Strickland (16918353) (author), Binita Chakraborty (16918356) (author), Sandeep Artham (15086158) (author), Regina S. Whitaker (16918359) (author), Katherine Hebert (16918362) (author), Jake Fontenot (16918365) (author), Steven R. Patierno (16918368) (author), Jennifer A. Freedman (16918371) (author), Frank H. Lau (16918374) (author), Matthew E. Burow (16918377) (author), Ching-Yi Chang (15134445) (author), Donald P. McDonnell (15051446) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Signaling Protein serine-threonine kinases Drug Targets Protein kinase & phosphatase drug targets Progression, Invasion & Metastasis Metastasis Migration and invasion
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Video 2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Yazar:: Debarati Mukherjee (15134436)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video 3 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Yazar:: Debarati Mukherjee (15134436)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Yazar:: Debarati Mukherjee (15134436)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S1 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S2 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S6 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S8 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S9 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Yazar:: Jesse C. Patterson (14962862)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Yazar:: Clare F. Malone (14960925)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Yazar:: Clare F. Malone (14960925)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Yazar:: Clare F. Malone (14960925)
Baskı/Yayın Bilgisi: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Yazar:: Evan C. Chen (15054014)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Yazar:: Evan C. Chen (15054014)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Yazar:: Evan C. Chen (15054014)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Yazar:: Evan C. Chen (15054014)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Yazar:: Evan C. Chen (15054014)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Yazar:: Evan C. Chen (15054014)
Baskı/Yayın Bilgisi: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Yazar:: Srivandana Akshintala (16610490)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Yazar:: Srivandana Akshintala (16610490)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jp1vqq2nn1c65crjmh4v42hj4n